ArticleJournal of nanobiotechnology2025
Peptide-modified phase-transition nanoparticles co-deliver FTO siRNA and Ce6 for sonodynamic metabolism-immunotherapy of melanoma.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Reader-dependent functional duality of FTO: a context-switching node at the intersection of immune evasion and therapeutic resistance.Frontiers in immunology · 2026Review
- Enhancing targeted strategies for cancer immunotherapy by elucidating mRNA processing mechanisms.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundMelanoma, the most aggressive skin cancer, remains challenging to treat due to limited therapeutic options. Sonodynamic therapy (SDT) has emerged as a promising strategy for combating malignant tumors. However, the excessive accumulation of lactate in the tumor microenvironment after SDT limits the activation of immune cells, leading to the unsatisfactory therapeutic effect of SDT. Fat mass and obesity-associated (FTO) inhibition can effectively inhibit glycolysis of melanoma cells and relieve the obstacle of immune cell activation caused by lactate. FTO inhibiting in tumors eliminates metabolic barriers to T cell activation and further enhances the antitumor effect of CD8 + T cells. Combining FTO inhibition with SDT may enhance tumor cell elimination and remodel the immunosuppressive tumor immune microenvironment.
methodsWe prepared nanoparticles through filming-rehydration method and the electrostatic adsorption method. The inhibition effects of nanoparticles on FTO and glycolysis were verified by detecting protein expression and lactate production. The therapeutic effect of nanoparticles on melanoma was evaluated by detecting the cytotoxicity of tumor cells and the infiltration of immune cells.
resultsIn this study, tLyp-1 modified ultrasound phase-transforming nanoparticles loaded with sonosensitizer (Ce6) and FTO siRNA were constructed to achieve FTO inhibition and SDT. The tLyp-1 peptide modification facilitated efficient tumor targeting function and enhanced deep tissue penetration, therefore improving drug delivery efficacy. Ce6 produced reactive oxygen species (ROS) in response to ultrasound to induce immunogenic cell death (ICD) in tumor cells. At the same time, ultrasound promoted FTO siRNA transfection to inhibit B16-F10 cells glycolysis, which significantly increased the activation and infiltration of dendritic cells (DCs) and T lymphocytes in the tumor microenvironment, effectively enhanced the therapeutic effect of SDT and inhibited tumor growth.
conclusionThis study demonstrated that si-Ce6@tLyP-1 NPs serve as a platform for targeted the tumor site and efficiently deliver siFTO and Ce6. The realization of FTO inhibition combined with SDT provides an effective treatment strategy for the treatment of melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.